217 related articles for article (PubMed ID: 36860124)
1. N6-methyladenosine-modified DBT alleviates lipid accumulation and inhibits tumor progression in clear cell renal cell carcinoma through the ANXA2/YAP axis-regulated Hippo pathway.
Miao D; Wang Q; Shi J; Lv Q; Tan D; Zhao C; Xiong Z; Zhang X
Cancer Commun (Lond); 2023 Apr; 43(4):480-502. PubMed ID: 36860124
[TBL] [Abstract][Full Text] [Related]
2. The methyltransferase METTL3 promotes tumorigenesis via mediating HHLA2 mRNA m6A modification in human renal cell carcinoma.
Zhu D; Liu Y; Chen J; Wang Q; Li Y; Zhu Y; Feng J; Jiang J
J Transl Med; 2022 Jul; 20(1):298. PubMed ID: 35794583
[TBL] [Abstract][Full Text] [Related]
3. NAT10-mediated ac
Miao D; Shi J; Lv Q; Tan D; Zhao C; Xiong Z; Zhang X
Cancer Commun (Lond); 2024 Mar; 44(3):361-383. PubMed ID: 38407929
[TBL] [Abstract][Full Text] [Related]
4. SH3BGRL2 inhibits growth and metastasis in clear cell renal cell carcinoma via activating hippo/TEAD1-Twist1 pathway.
Yin L; Li W; Xu A; Shi H; Wang K; Yang H; Wang R; Peng B
EBioMedicine; 2020 Jan; 51():102596. PubMed ID: 31911271
[TBL] [Abstract][Full Text] [Related]
5. METTL3 promotes colorectal carcinoma progression by regulating the m6A-CRB3-Hippo axis.
Pan J; Liu F; Xiao X; Xu R; Dai L; Zhu M; Xu H; Xu Y; Zhao A; Zhou W; Dang Y; Ji G
J Exp Clin Cancer Res; 2022 Jan; 41(1):19. PubMed ID: 35012593
[TBL] [Abstract][Full Text] [Related]
6. The m6A modification-mediated OGDHL exerts a tumor suppressor role in ccRCC by downregulating FASN to inhibit lipid synthesis and ERK signaling.
Shi J; Miao D; Lv Q; Wang K; Wang Q; Liang H; Yang H; Xiong Z; Zhang X
Cell Death Dis; 2023 Aug; 14(8):560. PubMed ID: 37626050
[TBL] [Abstract][Full Text] [Related]
7. METTL14-mediated N
Liu Z; Sun T; Piao C; Zhang Z; Kong C
Cell Commun Signal; 2022 Mar; 20(1):36. PubMed ID: 35305660
[TBL] [Abstract][Full Text] [Related]
8. YAP is overexpressed in clear cell renal cell carcinoma and its knockdown reduces cell proliferation and induces cell cycle arrest and apoptosis.
Cao JJ; Zhao XM; Wang DL; Chen KH; Sheng X; Li WB; Li MC; Liu WJ; He J
Oncol Rep; 2014 Oct; 32(4):1594-600. PubMed ID: 25175178
[TBL] [Abstract][Full Text] [Related]
9. E2F1 promotes proliferation and metastasis of clear cell renal cell carcinoma via activation of SREBP1-dependent fatty acid biosynthesis.
Shen D; Gao Y; Huang Q; Xuan Y; Yao Y; Gu L; Huang Y; Zhang Y; Li P; Fan Y; Tang L; Du S; Wu S; Wang H; Wang C; Gong H; Pang Y; Ma X; Wang B; Zhang X
Cancer Lett; 2021 Aug; 514():48-62. PubMed ID: 34019961
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of SAV1 plays a role in pathogenesis of high-grade clear cell renal cell carcinoma.
Matsuura K; Nakada C; Mashio M; Narimatsu T; Yoshimoto T; Tanigawa M; Tsukamoto Y; Hijiya N; Takeuchi I; Nomura T; Sato F; Mimata H; Seto M; Moriyama M
BMC Cancer; 2011 Dec; 11():523. PubMed ID: 22185343
[TBL] [Abstract][Full Text] [Related]
11. miR-10b suppresses cell invasion and metastasis through targeting HOXA3 regulated by FAK/YAP signaling pathway in clear-cell renal cell carcinoma.
He C; Chen ZY; Li Y; Yang ZQ; Zeng F; Cui Y; He Y; Chen JB; Chen HQ
BMC Nephrol; 2019 Apr; 20(1):127. PubMed ID: 30975094
[TBL] [Abstract][Full Text] [Related]
12. Regulation of Hippo/YAP signaling and Esophageal Squamous Carcinoma progression by an E3 ubiquitin ligase PARK2.
Zhou X; Li Y; Wang W; Wang S; Hou J; Zhang A; Lv B; Gao C; Yan Z; Pang D; Lu K; Ahmad NH; Wang L; Zhu J; Zhang L; Zhuang T; Li X
Theranostics; 2020; 10(21):9443-9457. PubMed ID: 32863938
[No Abstract] [Full Text] [Related]
13. Overexpression of DBT suppresses the aggressiveness of renal clear cell carcinoma and correlates with immune infiltration.
Zhang C; Huang G; Yang J; Jiang Y; Huang R; Ye Z; Huang Y; Hu H; Xi X
Front Immunol; 2023; 14():1197011. PubMed ID: 37383233
[TBL] [Abstract][Full Text] [Related]
14. CCDC25 suppresses clear cell renal cell carcinoma progression by LATS1/YAP-mediated regulation of the hippo pathway.
Tan H; Liu J; Li Y; Mi Z; Liu B; Rong P
Cancer Cell Int; 2024 Apr; 24(1):124. PubMed ID: 38570766
[TBL] [Abstract][Full Text] [Related]
15. MiR-212-5p inhibits the malignant behavior of clear cell renal cell carcinoma cells by targeting TBX15.
Deng JH; Zheng GY; Li HZ; Ji ZG
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(24):10699-10707. PubMed ID: 31858538
[TBL] [Abstract][Full Text] [Related]
16. METTL14-mediated N6-methyladenosine modification of Pten mRNA inhibits tumour progression in clear-cell renal cell carcinoma.
Zhang L; Luo X; Qiao S
Br J Cancer; 2022 Jul; 127(1):30-42. PubMed ID: 35249103
[TBL] [Abstract][Full Text] [Related]
17. The N6-methyladenosine METTL3 regulates tumorigenesis and glycolysis by mediating m6A methylation of the tumor suppressor LATS1 in breast cancer.
Xu Y; Song M; Hong Z; Chen W; Zhang Q; Zhou J; Yang C; He Z; Yu J; Peng X; Zhu Q; Li S; Ji K; Liu M; Zuo Q
J Exp Clin Cancer Res; 2023 Jan; 42(1):10. PubMed ID: 36609396
[TBL] [Abstract][Full Text] [Related]
18. AUP1 regulates lipid metabolism and induces lipid accumulation to accelerate the progression of renal clear cell carcinoma.
Chen C; Zhao W; Lu X; Ma Y; Zhang P; Wang Z; Cui Z; Xia Q
Cancer Sci; 2022 Aug; 113(8):2600-2615. PubMed ID: 35633317
[TBL] [Abstract][Full Text] [Related]
19. Hippo signaling mediates proliferation, invasiveness, and metastatic potential of clear cell renal cell carcinoma.
Schütte U; Bisht S; Heukamp LC; Kebschull M; Florin A; Haarmann J; Hoffmann P; Bendas G; Buettner R; Brossart P; Feldmann G
Transl Oncol; 2014 Apr; 7(2):309-21. PubMed ID: 24913676
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of Hippo signalling activity in different histopathologic subtypes of renal cell carcinoma.
Duong NX; Le MK; Kondo T; Mitsui T
J Cell Mol Med; 2023 Jan; 27(1):66-75. PubMed ID: 36478130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
